Vascular pericytes, an important cellular component in the tumor microenvironment, are often associated with tumor vasculatures, and their functions in cancer invasion and metastasis are poorly understood. Here we show that PDGF-BB induces pericyte-fibroblast transition (PFT), which significantly contributes to tumor invasion and metastasis. Gain-and loss-of-function experiments demonstrate that PDGF-BB-PDGFRβ signaling promotes PFT both in vitro and in in vivo tumors. Genome-wide expression analysis indicates that PDGF-BB-activated pericytes acquire mesenchymal progenitor features. Pharmacological inhibition and genetic deletion of PDGFRβ ablate the PDGF-BB-induced PFT. Genetic tracing of pericytes with two independent mouse strains, TN-AP-CreERT2:R26R-tdTomato and NG2-CreERT2:R26R-tdTomato, shows that PFT cells gain stromal fibroblast and myofibroblast markers in tumors. Importantly, coimplantation of PFT cells with less-invasive tumor cells in mice markedly promotes tumor dissemination and invasion, leading to an increased number of circulating tumor cells and metastasis. Our findings reveal a mechanism of vascular pericytes in PDGF-BB-promoted cancer invasion and metastasis by inducing PFT, and thus targeting PFT may offer a new treatment option of cancer metastasis.
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pericyte | PDGF | fibroblast | metastasis | mesenchymal cell T he tumor microenvironment possesses diverse cellular components including malignant cells, inflammatory cells, stromal fibroblasts, various progenitor cells, endothelial cells, and perivascular cells. These tumor-associated cellular components constantly change their identities and functions to cope with tumor growth and invasiveness (1) . Tumor cells often produce various growth factors and cytokines as instrumental signals to manipulate host cells that in most cases facilitate tumor growth and metastasis. Although the role of endothelial, inflammatory, and mesenchymal cells in tumor growth and invasion have been extensively studied (2-10), functions of pericytes in the tumor microenvironment remain largely unknown.
Pericytes are mainly described as mural cells that are associated with vasculatures in various healthy and pathological tissues (11) . Recruitment of pericytes to newly formed angiogenic vessels prevents excessive sprouting, stabilizes the nascent vasculature, prevents vascular leakiness, and remodels primitive vasculatures toward mature vasculatures (12, 13) . It is believed that these vasculature-related pericyte functions could possibly impede tumor invasion and metastasis. Recent studies show that pericytes retain progenitor cell properties and can differentiate into other cells, including adipocytes, chondrocytes, osteoblasts, phagocytes, granulocytes, and skeletal muscle (14) (15) (16) (17) (18) . Under pathological conditions, pericytes may differentiate into myofibroblasts, contributing to kidney fibrosis (19, 20) . Unlike most host cells in tumors, pericytes exhibit unique features by expressing a number of surface markers and respond to certain growth factors. The PDGF-BB-PDGFRβ signaling pathway is best known for its modulation of pericyte coverage on microvessels, and endothelial cells are the primary source of PDGF-BB (11) . Endothelial cell-derived PDGF-BB recruits pericytes onto angiogenic vessels through activation of PDGFRβ. Deletion of Pdgfb or Pdgfrß genes in mice resulted in vascular defect-related embryonic lethality due to lack of pericytes (21, 22) , indicating the pivotal role of PDGF-BB-PDGFRβ signaling in pericyte biology. Various tumors also express a high level of PDGF-BB and the impact of tumor cell-derived PDGF-BB on pericytes is controversial. In contrast to endothelial cells, tumor cell-derived PDGF-BB may potentially attract pericytes to migrate from vessels through a chemoattractant gradient mechanism (23) . The fate of vessel disassociated pericyte (PC) has not been clearly investigated. PDGF receptor signaling has been suggested to contribute to pericyte-myofibrolast transition in kidney fibrosis (19) .
CAFs, especially myofibroblasts, are known to facilitate tumor invasion and metastasis (6) . In certain tumor types such as pancreatic cancers, CAFs dominate tumor cellular components and constitute a major part of the tumor mass (24) . Unresolved key issues include the origin of CAFs and the signaling pathways that control the CAF population in tumor tissues. Could it be
Significance
We show that vascular pericytes significantly contribute to cancer invasion and metastasis by the mechanism of the pericytefibroblast transition (PFT). This study proposes this concept and indicates the vascular pericyte's role. Vascular pericytes were considered to remodel tumor vessels toward a mature phenotype. However, once dissociated from tumor vessels their functions within the tumor tissue are not known. In the present study, we show that pericytes, once detached from tumor microvasculatures, underwent differentiation to become stromal fibroblasts, which are known to contribute to tumor invasion and metastasis. Our results show that vascular pericytes are the important source of stromal fibroblasts and targeting PFT may offer a new treatment option in cancer metastasis.
possible that other host cells in tumors differentiate into CAFs under the influence of specific signaling systems? In the present study, we provide evidence to demonstrate that vascular pericytes are an important source of CAFs, which markedly promote cancer metastasis. The pericyte-CAF transition is modulated by PDGF-BB-PDGFRβ signaling through the mechanism of pericyte-fibroblast transition (PFT). Gain-and loss-of-function experiments using genetic and pharmacological approaches validate that PFT in tumors is the primary driving force for cancer invasion and metastasis. Genetic tracing in tumor-bearing mice demonstrates that a significant number of pericytes undergo PFT. Finally, we provide evidence that PDGF-BB expression levels and fibroblast components correlate with poor survival in patients with different cancer types. Thus, our findings are clinically relevant and shed mechanistic insights on pericyte-mediated cancer metastasis and suggest that targeting PFT may potentially offer a new therapeutic option for cancer treatment.
Results

PDGF-BB Expression and Stromal Fibroblast Components in Naturally
Occurring Human Tumors. To study the role of PDGF-BB, the pluripotent member of the PDGF family, in supporting CAFs, we analyzed expression levels of PDGF-BB mRNA and protein in a dozen human tumor cell lines. We previously reported a high PDGF-BB expression level in SC-A431 squamous carcinoma tumor tissue and a low PDGF-BB expression level in NB-IMR32 neuroblastoma tumor tissue (23) . We have now validated those in vivo findings with in vitro cell cultures. Naturally occurring SC-A431 squamous carcinoma cells expressed a high level of PDGF-BB (40 pg/mL) in a 48-h-conditioned medium (Fig. 1A) . In contrast, a renal cell carcinoma (RCC-CAKI-1) and a neuroblastoma (NB-IMR32) have undetectable levels of PDGF-BB.
Immunohistochemical staining of tumor tissues showed that these tumors contained high densities of microvessels and decreased NG2 + pericyte area (Fig. 1B) (23) . SC-A431 tumors possessed high content of fibroblast-specific protein 1 (FSP1) + stromal fibroblast and α-smooth muscle actin (αSMA) + myofibroblast components ( Fig. 1 C and D) . To exclude the possibility that αSMA + cell populations were vascular smooth muscle cells (VSMCs), tumor tissues were costained with αSMA and endomucin (a pan-endothelial cell specific marker). Notably, the majority of αSMA + cell populations did not show association with endomucin + positive signals (Fig. 1C) , suggesting that the majority of αSMA + cells were myofibroblasts but not VSMCs. In contrast to SC-A431, both RCC-CAKI-1 and NB-IMR32 tumors have much fewer FSP1 + and αSMA + fibroblast components. These findings suggest a possible link between PDGF-BB expression and high content of CAFs in naturally occurring human tumors.
Genetic Knockdown and Pharmacological Inhibition of the PDGF-BB-PDGFR Signaling Ablates CAFs in Human Tumors. To investigate the relation between PDGF-BB expression and the stromal CAF composition in SC-A431 tumors, Pdgfb mRNA was knocked down using a specific shRNA. This approach effectively ablated the expression level of Pdgfb (Fig. S1A) . Knockdown of Pdgfb significantly increased pericyte coverage in tumor microvessels ( Fig. 1 E and F) .
Conversely, FSP1
+ and αSMA + stromal fibroblasts and myofibrolasts were markedly decreased in Pdgfb-shRNA-transfected compared with scrambled-shRNA-transfected SC-A431 tumors ( Fig. 1 E and F) .
To further validate these findings, SC-A431 tumors were treated with imatinib, a BCL-ABL tyrosine kinase inhibitor with a potential inhibitory effect on the PDGFR signaling (25) (26) (27) . Imatinib inhibited SC-A431 tumor growth and the tumor growth of other cell lines as previously described (23, 28) . Similar to the shRNA knockdown approach, imatinib treatment also restored pericyte coverage in tumor microvessels as previously described (23) . Importantly, treatment with imatinib markedly reduced the stromal FSP1
+ fibroblast and αSMA + myofibroblast components in tumors ( Fig. 1 G and H ). These data demonstrate that the PDGF-BB-PDGFR signaling significantly contributes to increases of CAFs in naturally occurring human tumors.
Gain of Function of PDGF-BB in Mouse Tumors Enhances CAFs and
Decreases Pericytes. To further validate our findings in naturally occurring human tumors, we next performed a gain-of-function experiment by overexpressing PDGF-BB in mouse tumors that lacked detectable PDGF-BB as previously described (23) . Similar to human SC-A431 tumors, overexpression of PDGF-BB in T241 fibrosarcoma and Lewis lung carcinoma (LLC) nearly completely ablated pericytes in tumors as previously described (23) . Both vessel-and nonvessel-associated pericytes were depleted by overexpression of PDGF-BB (23) . The decrease in pericytes in PDGF-BB-expressing T241 and LLC tumors was not due to pericyte apoptosis, because the pericyte apoptotic rates in PDGF-BB + and PDGF-BB − tumors were similar (Fig.  S2A) . Expression of PDGF-BB in T241 and LLC tumors led to a marked increase of FSP1 + stromal fibroblasts and αSMA + myofibrolasts, which were disassociated with tumor microvasculatures ( Fig. S2 B-E). Consequently, total amounts of stromal components in these PDGF-BB-expressing tumors were markedly increased relative to PDGF-BB-negative tumors (Fig. S2F ). These gain-of-function experiments provide independent evidence that PDGF-BB is primarily responsible for recruitment of CAFs and cancer-associated myofibroblasts (CAMFs). Additionally, PDGFRβ blockade treatment markedly decreased the populations of FSP1
+ stromal fibroblasts and αSMA + myofibrolasts in tumors ( Fig. S2 G and H) . In contrast to PDGFRβ blockade, anti-PDGFRα treatment did not significantly alter the FSP1 + and αSMA + stromal fibroblast components in PDGF-BBexpressing tumors ( Fig. S3 A and B) , suggesting that PDGF-BB-PDGFRα signaling is not significantly involved in mediating the PDGF-BB-induced expansion of stromal fibroblasts. Similar to PDGFRβ blockade, treatment of T241-PDGF-BB tumors with imatinib resulted in nearly identical effects of pericyte restoration and loss of CAFs and CAMFs ( Fig. S2 G and H) . Also, treatment with an anti-PDGFRα neutralizing antibody increased NG2
+ signals that were disassociated with blood vessels (Fig. S3 C and D) . In addition to alterations of pericytes and stromal fibroblasts, treatment using imatinib, but not anti-PDGFRα, significantly inhibited tumor angiogenesis (20) . Both anti-PDGFRβ and imatinib treatments significantly inhibited the growth rates of T241-PDGF-BB tumors as previously described (23) . In contrast, treatment using anti-PDGFRα antibody did not alter the tumor growth rate significantly (Fig. S3E) . To further validate our findings, we treated the established tumors (tumor size around 0.4 cm 3 ) with PDGFRβ blockade and imatinib and obtained nearly identical results of fibroblast loss, reduction of stromal components, and inhibition of the tumor growth rate (Fig. S4) . These gain-of-function results from mouse models validate our findings in human tumor models that the PDGFRβ-mediated signaling pathway is critical for the expansion of CAFs and CAMFs in tumors.
Genetic Deletion of PDGFRβ in Mice Attenuates PDGF-BB-Recruited
Stromal Fibroblasts and Myofibrolasts. To further define the receptor signaling pathways that mediate PDGF-BB-recruited CAFs and CAMFs, we genetically deleted PDGFRβ in mice in a conditional knockout model (29, 30) . Deletion of PDGFRβ significantly decreased vascular pericyte coverage in PDGF-BBnegative control vector tumors, supporting the vascular function of PDGF-BB in recruitment of pericytes to angiogenic vessels ( PDGF-BB Promotes PFT of Isolated Mouse Pericytes. The loss of NG2 + pericytes and increase of CAFs and CAMFs in PDGF-BB-expressing tumors suggested that vascular pericytes might undergo differentiation into stromal fibroblasts. To investigate this possibility, we isolated primary pericytes and stimulated them with PDGF-BB in vitro for an extended period. First, we observed that PDGF-BBstimulated pericytes changed their morphologies to an elongated and spindle-like cell shape that was morphologically similar to that of fibroblasts ( Fig. 2 A and B) , and PDGF-BB had no effect on pericyte apoptosis compared with vehicle-stimulated controls ( Fig. 2 A and B) . Surprisingly, the PDGF-BB-stimulated pericytes gained FSP1 expression, a fibroblastspecific marker, indicating that pericytes underwent a PFT transition ( Fig. 2 A and B) . The loss of expression of NG2 and gain of expression of FSP1 were further validated by Western immunoblot with specific antibodies (Fig. 2C) .
We used anti-PDGFRα and anti-PDGFRβ specific neutralizing antibodies to delineate the receptor signaling responsible for PDGF-BB-induced PFT (23, 30) . PDGFRβ neutralizing antibody blocked the PDGF-BB-induced PFT, whereas the anti-PDGFRα specific antibody had virtually no effect (Fig. 2D) . Similarly, imatinib also effectively inhibited the PDGF-BBinduced PFT in this in vitro experiment setting. Both anti-PDGFRβ and imatinib prevented the loss of NG2 in pericytes (E) DiI-labeled pericytes (green) were implanted into T241-vector and T241-PDGF-BB tumors. Tumor vessels were stained with CD31 (red in Top), pericytes were stained with NG2 (red in Middle), and fibroblasts were stained with FSP1 (red in Bottom). ( Fig. 2D) . These data show that PDGF-BB is capable of inducing PFT in isolated pericytes. To further study whether PDGF-BB was able to induce PFT in in vivo tumors, isolated pericytes were labeled with DiI dye and injected into PDGF-BB and vector tumors. Consistent with in vitro findings, NG2
+ pericytes lost NG2 expression in PDGF-BB fibrosarcomas and gained FSP1 expression (Fig. 2 E and F) . Similar results were also obtained from an independent PDGF-BB-expressing tumor, LLC-PDGF-BB (Fig. S6 C and D) . Thus, PDGF-BB-induced PFT occurs in tumors in vivo.
Primary Pericytes Isolated from Human Tumors Undergo PFT in in Vivo
Tumors. To link our findings to clinical relevance, we isolated primary pericytes from fresh human tumors using NG2 as a specific marker (Fig. 2 G-I) . The isolated human pericytes were labeled with DiI dye and injected into naturally occurring human squamous carcinomas implanted in immunodeficient SCID mice. Injection of human pericytes into control shRNA-A431 human squamous carcinoma resulted in disassociation of pericytes from tumor vasculatures and gain of FSP1 and αSMA expression (Fig.  2 J and K) . However, knockdown of PDGF-BB by a shPdgfb markedly inhibited PFT and the remaining pericytes were associated with tumor vessels (Fig. 2 J and K) . To further validate these findings in human tumors, DiI-labeled isolated human pericytes were also injected into mouse tumors. Similar to human tumors, PDGF-BB disassociated pericytes from tumor vasculatures and stimulated PFT by gaining FSP1 and αSMA expression and loss of NG2 expression (Fig. 2 L and M) . Taken together, these findings show that pericytes isolated from human tumor tissues are capable of PFT in human and mouse tumors. Thus, it is highly plausible that PFT also occurs in human tumors.
Genome-Wide Profiling Defines Fibroblast-Like Signatures of PDGF-BB-Stimulated Pericytes. To further define fibroblast signatures in PDGF-BB-stimulated pericytes, we performed genome-wide gene expression profiling and revealed marked changes of clusters of genes in PDGF-BB-stimulated and nonstimulated pericytes (Fig. 3A) . A multiclass rank product analysis identified differentially expressed genes. Gene set enrichment analysis showed that proliferation was strongly induced early at day 1 but was later decreased at day 5 after PDGF-BB stimulation (Fig.  3B) . A gene set representing epithelial-to-mesenchymal transition was enriched among up-regulated genes both after day-1 and day-5 stimulation with PDGF-BB (Fig. 3B) . A heat map of known marker genes for pericytes, fibroblasts, and mesenchymal cells showed that PDGF-BB treatment of primary pericytes induced differentiation toward a fibroblast fate (Fig. 3C) . Further analysis of stromal or mesenchymal cell-related genes using the random variance model supported the PDGF-BB-stimulated PFT (Fig. 3D) . Further, we used a known mesenchymal fibroblast cell (S17) as a positive control to profile the similarities of up-and down-related genes in PDGF-BB-stimulated pericytes. Strikingly, we found that 77% of up-and down-regulated genes were in agreement with the fibroblast signature (Fig. 3E) . Taken together, the genome-wide gene expression analysis demonstrates that PDGF-BB-stimulated pericytes possess fibroblast features.
Genetic Tracing of PFT in Tumors with Two Independent Mouse Strains.
To provide definite evidence to further support the PDGF-BBinduced PFT, we generated two tumor models using genetically modified mouse strains that allowed us to trace pericytes in the tumor microenvironment. In the first model (TN-AP Cre ERT2:R26R-tdTomato), pericytes were genetically labeled with Tomato Red as previously described (15) . Both T241 vector and PDGF-BB-expressing tumors were implanted in TN-AP Cre ERT2:R26R-tdTomato mice. Expectedly, Texas Red tomato-labeled pericytes were mainly associated with tumor vasculatures in the vector tumors and a substantial number of Texas Red Tomatolabeled pericytes expressed NG2 marker (Fig. 4 A and B) . In contrast, most Texas Red tomato-labeled pericytes lost NG2 expression and their association with tumor vasculatures in PDGF-BB tumors. Instead, these Texas Red tomato-labeled cells exhibited elongated morphologies typical of fibroblasts in appearance. Moreover, these labeled pericytes gained expression of FSP1 and PDGFRα, two commonly expressed cell surface markers in stromal fibroblasts (Fig. 4 A and B) . These findings support the notion that genetically labeled pericytes in the tumor microenvironment undergo PFT in response to PDGF-BB stimulation.
To further validate these findings, we chose to use an independent mouse tracing strain in which specific expression of Texas Red Tomato was controlled by the NG2 Cre recombinase (NG2 Cre ERT2:R26R-tdTomato) (31) . Again, in the vector tumor, most NG2 Texas Red Tomato-labeled pericytes were associated with tumor vessels and they retained their NG2 expression (Fig.  4 C and D) . Strikingly, almost all NG2 Texas Red Tomato-labeled pericytes lost their NG2 expression and association with tumor vasculatures in PDGF-BB tumors, supporting our findings in nongenetically manipulated WT mice. In contrast, NG2 Texas Red Tomato-labeled pericytes significantly gained expression of FSP1 and PDGFRα (Fig. 4 C and D) . These findings support PDGF-BB-triggered PFT in the tumor microenvironment.
PDGF-BB-Primed Pericytes Stimulate Tumor Growth and Metastasis.
We next investigated functional impacts of PDGF-BB-stimulated pericytes in tumor growth and metastasis. Pericytes were stimulated with PDGF-BB-containing medium for 7 d and were subsequently coimplanted with EGFP-T241 tumor cells. Nonstimulated pericytes were used as controls. At day 24 after implantation, the PDGF-BB-pericytes+ tumor cell group grew significantly faster compared with the vehicle pericytes+ tumor cell group, indicating that PDGF-BB-stimulated pericytes play a significant role in stimulating tumor growth (Fig. 5A) . Histological examination showed that tumors with PDGF-BB-stimulated pericytes possessed a higher density of microvessels relative to control tumors ( Fig. 5 B and C) . However, percentages of pericyte coverage in both PDGF-BB-pericyte and vehicle-pericyte+ tumors were identical (Fig. 5 B  and C) , suggesting that in vitro stimulation of pericytes with PDGF-BB did not affect their association with angiogenic vessels. Conversely, FSP1
+ CAFs were markedly increased in PDGF-BB-pericyte tumors compared with control tumors (Fig.  5D) , supporting the view that PDGF-BB-stimulated pericytes underwent PFT transition.
It is known that increases of CAFs and angiogenic phenotype are correlated with invasiveness and metastatic phenotypes of solid tumors (6) . To study the impact of PDGF-BB-stimulated pericytes in promoting cancer metastasis, we measured the number of circulating tumor cells (CTCs) in PDGF-BB-pericytes-and vehicle-pericytescontaining tumor-bearing mice. Interestingly, a significantly higher number of CTCs were found in PDGF-BB-pericytes-containing tumor-bearing mice compared with vehicle-pericytes-containing tumor-bearing mice (Fig. 5E ). These data suggest that PDGF-BBstimulated pericytes promote tumor cell intravasation in the primary sites. Consistent with increases of CTCs, culturing blood from PDGF-BB-pericytes-containing tumor-bearing mice resulted in a significantly increased number of tumor colonies compared with control group (Fig. 5F ). Taken together, these results show that PDGF-BB-stimulated pericytes facilitate primary tumor growth and cancer metastasis through the mechanisms of tumor angiogenesis and intravasation. Liver implantation of T241-PDGF-BB-EGFP and T241-vector-EGFP tumors allowed us to visualize the invasive front of tumor masses. T241-PDGF-BB tumors showed irregular fronts with invasive tumor cells compared with control tumors (Fig. 5  G-I) . Importantly, numbers of FSP1 + and αSMA + CAFs in PDGF-BB tumors were markedly increased in the invasive front of PDGF-BB tumors compared with those in control tumors (Fig. 5 H and I) , suggesting that these CAFs, likely to be originated from pericytes, are involved in tumor invasion and metastasis. To further delineate the role of pericytes in tumor invasion, we coimplanted EGFP-T241 tumors with PDGF-BBor vehicle-stimulated pericytes. Interestingly, coimplantation of PDGF-BB-stimulated pericytes with tumor cells resulted in an invasive phenotype and invasive scattered tumor cells could be detected in the tumor rims (Fig. 6 A-C) . Again, high densities of FSP1 + and αSMA + CAFs were accrued at the invasive leading front in tumors with PDGF-BB-stimulated pericytes compared with tumors containing vehicle-stimulated pericytes (Fig. 6 A-C) . These data provide an independent line of evidence that PDGF-stimulated pericytes promote tumor invasiveness in the invasive tumor front.
Reverse Correlation of High PDGFB and FSP1 Expression with Survival in Colorectal, Glioblastoma Multiforme, and Lung Cancer Patients. To relate our preclinical findings to clinical relevance, we performed metaanalyses of cancer patients to correlate PDGFB and FSP1 expression levels to survival. Because cancer invasion and metastasis are the most common causes of cancer-related death, survival prognosis often reflects the invasive and metastatic situation of cancer patients. We chose three common cancers, including lung squamous cell carcinoma (LUSC), colorectal adenocarcinoma (COADREAD), and lower-grade glioma (LGG), for further analysis. In this clinical study, datasets of 391 LUSC, 72 COADREAD, and 212 LGG patients were included in our study. Numbers of PDGFBlow patients include 192 LUSC, 36 COADREAD, and 105 LGG, and PDGFB-high patients include 199 LUSC, 36 COADREAD, and 107 LGG. Markedly, PDGFB-high groups in all three cancer types showed significantly shortened survivals compared with their corresponding PDGFB-low groups (Fig. 6 D-F) .
We next correlated PDGFB-high and -low groups with the FSP1 expression levels in these tumors. Strikingly, FSP1
+ fibrotic contents were significantly higher in PDGFB-high groups compared with PDGFB-low groups of these cancer patients (Fig. 6  G-I) . The results from three cohort analyses provide clinical evidence of reverse correlation between PDGFB and FSP1 expression with survival. Based on these clinical findings, it is reasonable to speculate that PDGFB and FSP1 could potentially serve as prognostic markers to predict survivals of LUSC, COADREAD, and LGG patients.
Discussion
CAFs are one of the major host cellular components in many solid tumors, and infiltration of this stromal component has been correlated with invasiveness and poor prognosis of cancer disease (5, 6) . In this study, we address an important issue related to the origin of CAFs in the tumor microenvironment. We have revealed a mechanism by which perivascular cells serve as a reservoir for stromal fibroblasts and the PFT is controlled by tumor-derived factors. Our study provides another example of how tumor cells manipulate the host-cell interaction for their growth and invasion. Although genetic mutations in malignant cells are important for tumor growth and invasion, the microenvironment composed of host cells is a crucial element that determines the invasive phenotype of tumor cells. To metastasize to distal organs, malignant cells at the primary site have to interact with host cells, including inflammatory cells, fibroblasts, and vascular cells, to intravasate into the circulation (32, 33) . Intravasation, one of the initial steps of the metastatic cascade, is a complex process that requires several cell types to interact and transmigrate through the vascular endothelium in a cooperative manner. Several key issues related to tumor cell invasion and the underlying molecular mechanism remain unclear. How is this multicellular process modulated in the tumor microenvironment? What are the origins of CAFs? What are the functions of perivascular cells in cancer metastasis? How are these host cells positioned at the invasive fronts? What are the signaling molecules and pathways that control tumor invasion? Whereas most host-cell types in the tumor microenvironment, including inflammatory cells, endothelial cells, and stromal fibroblasts, are well-characterized, the biological functions of pericytes in association with cancer metastasis remain largely unknown. Would high numbers of pericytes be advantageous for tumor growth and metastasis? If so, would associated or diassociated pericytes facilitate tumor growth and metastasis? In tumors, pericytes are widely believed to play a role in the recruitment of pericytes onto angiogenic vessels, leading to vascular remodeling toward a maturation phenotype (12, 16) . PDGF-BB is one of the key factors involved in pericyte migration and association with angiogenic vessels. Disruption of pericyte coverage in tumor angiogenic vessels would likely increase the tortuosity and disorganization of tumor vessels, resulting in an accelerated tumor growth rate (34) . In support of this view, ablation of pericytes by anti-PDGF agents has been reported to increase vascular tortuosity and tumor growth, suggesting that vascular recruitment of pericytes by PDGF-BB plays a negative role in tumor angiogenesis and growth (35, 36) . Paradoxically, inhibition of PDGF-BB-mediated pericyte association to tumor vessels has also been reported to be a valid target for cancer therapy, particularly when targeted in combination with other angiogenic factors (35, (37) (38) (39) . For example, combining anti-VEGF and anti-PDGF drugs provides an additive therapeutic effect (40) . One explanation of the combination approach is that anti-PDGF drugs increase exposure of vascular endothelial cells to anti-VEGF agents by ablating perivascular cells. Despite these claims of vasculature-related functions, the action of pericytes per se on modulation of the tumor microenvironment, tumor growth, and metastasis are poorly understood. In particular, molecular players controlling pericyte differentiation in tumors remain unidentified. We are beginning to understand the complex role of pericytes in modulation of cancer metastasis. Our recent work and work published by others shows that loss of pericytes makes the tumor vessels more susceptible for cancer cell intravasation and eventually metastasis (23, 41) . Apart from pericytes and malignant cancer cells, other cell types such as tumor-associated macrophages and cancerassociated fibroblasts are also involved in the intravasation cascade (6, 33) . Loss of pericytes from tumor vessels may either permit tumor cell intravasation and PFT or hijack tumor cells for intravasation, and perhaps even the formation of the initial metastatic niches in distal tissues and organs. Indeed, it has been described that tumors can carry their own fibroblasts as "soil" for them to "seed" and grow in distal organs (42) . Therefore, pericytes play dynamic roles in cancer invasion and metastasis.
In this study, we show that PDGF-BB plays dual roles in modulation of pericyte functions. First, tumor cell-derived PDGF-BB ablates pericytes from tumor microvessels. The possible mechanism underlying pericyte ablation is that the high PDGF-BB gradient from the tumor cell source attracts pericytes to move toward tumor cells rather than to endothelial cells (23) . Second, once pericytes disassociate from tumor vasculatures, they undergo PFT under persistent PDGF-BB stimulation in the tumor microenvironment (Fig. 6J) . These findings may imply that (i) pericytes have an intrinsic property that displays high potential capacity and plasticity of differentiating into other cell types, (ii) endothelial cells in the vessel wall might prevent differentiation of pericytes into other cell types and maintain pericyte stemness features, and (iii) under the influence of a specific signaling pathway pericytes may commit to differentiation toward a specific cell type. In our mouse and human tumor experimental models we demonstrate that the PDGF-BB-PDGFRβ signaling system drives pericyte differentiation toward fibroblasts. It is unclear whether the PDGF-BB-PDGFRβ signaling pathway either alone or in combination with other signaling pathways induces pericyte differentiation toward other lineages.
One of the surprising findings of our present work is that PDGF-BB-expressing tumors almost completely lack NG2 + pericyte expression. Assuming that tumor cell-derived PDGF-BB ablates pericytes from tumor vessels, these NG2 + pericytes would have remained as vessel-disassociated NG2 + cells, which would still be detected. The loss of NG2 + cells is neither due to down-regulation of this cell surface marker by PDGF-BB stimulation nor to increased cell death. Two genetic tracing mouse strains provide compelling and convincing evidence supporting PFT. Although it is known that PDGF-BB tumors contain high amounts of stromal components (30) , their origins remain unclear. There are three possible mechanisms by which PDGF-BB contributes to the tumor stromal cell component: (i) induction of proliferation of existing fibroblasts for expansion, (ii) recruitment of fibroblasts from neighbor or distal tissues because PDGF-BB is a potent factor for cell migration, and (iii) differentiation of stem cells and other cell types into fibroblasts. Here, we demonstrate pericyte differentiation as a mechanism of increasing fibroblast components in PDGF-BB tumors. Our data could also be applicable in PDGF-BB negative tumors because PDGFRβ could be activated by alternative mechanisms. For example, other members in the PDGF family, including PDGF-DD and PDGF-CC, could also activate PDGFRβ (43) (44) (45) (46) . Moreover, genetic mutations of PDGFRβ could cause ligand-independent activation of this receptor (47) . Also, high expression of PDGFRβ in pericytes and stromal cells might cause autophosphorylation of PDGFRβ, leading to the formation of receptor dimers, oligomers, and aggregates (48) (49) (50) . These interesting possibilities warrant future validation.
Preclinical and clinical evidence shows that the tumor stroma is strongly correlated with an invasive and metastatic phenotype of most solid tumors (51) (52) (53) . In a mouse experimental metastatic model in our previous study we showed that PDGF-BB-producing tumor cells readily form clusters and are colonized in distal tissues and organs such as the lung (23) . These findings are consistent with results by others demonstrating that stromal fibroblasts promote metastatic tumor growth via stimulation of tumor angiogenesis (37) . Moreover, in the tumor environment, angiogenic vessels would facilitate pericyte infiltrations, which would subsequently undergo PFT by PDGF-BB. CAFs are crucial for the formation of tumor niches, and they often serve as feeder cells that support malignant cell adhesion, expansion, and invasion. Thus, tumor-derived PDGF-BB contributes to the metastatic cascade by facilitating multiple steps including stimulation of dissemination, recolonization, and regrowth. Our findings from animal tumor models are highly relevant to clinical settings in which human tumors produce high levels of PDGF-BB. Similar to genetically engineered mouse tumors, we provide evidence that human PDGF-BB-producing tumors in their intrinsic status exhibit pericyte ablation and disassociation from tumor vessels. Conversely, we demonstrate substantial expansion of the stromal compartment in PDGF-BB-positive tumors compared with PDGF-BB-negative tumors. Thus, these findings recapitulate the clinical situation in cancer patients. A rational speculation of our work is that PDGF-BB might serve as an important biomarker for predicting tumor invasion, metastasis, and drug resistance.
Our clinical data support the fact that high PDGFB expression in human cancers is reversely correlated with survival prognosis. In three cohort analyses of LUSC, COADREAD and LGG we show that high PDGFB levels serve as an independent prognostic marker for poor survival. Moreover, high PDGFB expression is positively correlated to the high content of stromal fibroblasts in tumors. Although tracing the fate of pericytes in human patients remains as a challenging issue because it cannot be performed, it is highly plausible that PDGF-BB is the driving force for expansion of CAFs in these cancer patients as well. In support of this notion, we demonstrate that pericytes isolated from human tumors are capable of undergoing PFT in human tumors. Because cancer metastasis is a common reason for cancer death, the reduced survival time of PDGFB-high and FSP1-high patients is likely due to cancer invasion and metastasis.
Taken together, our data provide evidence of cell-type switching in the tumor microenvironment and define functions of pericytes in cancer invasion and metastasis. Targeting the PDGF-BB-PDGFRβ-induced PFT would be an important therapeutic approach for the treatment of cancer and metastasis.
Materials and Methods
Animals. Male and female C57/B6 mice at age 4 to 6 wk were used for xenograft tumor studies. Male or female SCID mice, Pdgfrβ −/− mice, TN-AP Cre ERT2:R26R-tdTomato mice, and NG2 Cre ERT2:R26R-tdTomato mice at age 4 to 8 wk were used as knockout and transgenic mouse strains. All mouse studies were approved by the Northern Stockholm Experimental Animal Ethical Committee. See SI Materials and Methods for more details.
Human Samples. Human tissues materials were obtained from the Karolinska Hospital and the procedure of human sample handling and informed consent were followed according to the regulation approved by the Karolinska Biobank Review Board (permission no. BbK1228). Accordingly, all patient materials were anonymized before being transferred to research laboratories. Isolated cells from fresh human samples were injected into mice immediately without cultivation.
Cell Lines and Culture. T241, LLC, A431, and CAKI-1 tumor cell lines were cultured in DMEM. The IMR32 tumor cell line was maintained in RPMI1640 medium. Mouse primary PCs were maintained in DMEM. See SI Materials and Methods for details and also for details on Pdgfb-shRNA knockdown, whole-mount staining, immunohistochemical staining, isolation of primary pericytes from fresh human tumor tissues, measurement of CTC, ELISA, quantitative real-time and RT-PCR, immunoblotting, and correlation of PDGFB expression in human cancer patients.
Affymetrix Gene-Array Analysis. Data have been deposited in the Gene Expression Omnibus with accession nos. GSE85955 and GSE33717 (30) . See SI Materials and Methods for details.
Statistical Analysis. Statistical analyses of results except gene array analysis were performed using the standard two-tailed Student t test, and P < 0.05 was considered statistically significant.
